Brazil drugmaker EMS eyes overseas deals after buying Sanofi unit

Core Viewpoint - Brazilian drugmaker EMS is pursuing international expansion through acquisitions after acquiring Sanofi's Brazilian generic drugmaker Medley for over $500 million, aiming to strengthen its position in the generics market in Latin America [1] Company Developments - EMS plans to integrate Medley while also seeking additional acquisitions in Brazil, Mexico, and Eastern Europe, with a focus on becoming a more global company [1] - The acquisition of Medley could increase EMS's share of Brazil's generics market to approximately 30%, pending approval from antitrust regulator CADE [1] - EMS is preparing to launch its own semaglutide-based injector pens in Brazil, anticipating regulatory approval from Anvisa, as the patent for semaglutide is about to expire [1] Market Context - The generics market in Brazil includes strong competitors such as Cimed and Eurofarma, which may influence the approval process for the Medley acquisition [1] - Rival company Hypera plans to launch its generic version of semaglutide this year, indicating competitive dynamics in the market [1]